| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/09/2001 | CA2060176C Small particle drug compositions |
| 01/07/2001 | CA2313587A1 Capsule for controlled release of active substances |
| 01/06/2001 | CA2313339A1 Compositions containing fat-soluble substances in a carbohydrate matrix |
| 01/05/2001 | CA2314536A1 Stable microemulsions for the administration of fatty acids to humans or animals, and use of these microemulsions |
| 01/04/2001 | WO2001001140A1 Epitopes formed by non-covalent association of conjugates |
| 01/04/2001 | WO2001001139A2 Incorporation and appliations of biomolecular interactions within a carrier |
| 01/04/2001 | WO2001000883A1 Oligosaccharide-supplying compositions |
| 01/04/2001 | WO2001000832A1 Methods for making apo-2 ligand using divalent metal ions |
| 01/04/2001 | WO2001000808A1 Antisense modulation of ship-2 expression |
| 01/04/2001 | WO2001000680A1 Process for making cellulose ethers having reduced yellowing and discoloration |
| 01/04/2001 | WO2001000654A2 Purification and stabilization of peptide and proteins in pharmaceutical agents |
| 01/04/2001 | WO2001000563A1 Amorphous nitric esters and their pharmaceutical compositions |
| 01/04/2001 | WO2001000312A1 Spray drying process for preparing dry powders |
| 01/04/2001 | WO2001000253A1 Delivery of a botanical extract to a treated substrate for transfer to skin |
| 01/04/2001 | WO2001000247A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 01/04/2001 | WO2001000246A2 Hydrogels derived from chitosan and poly(ethylene glycol) |
| 01/04/2001 | WO2001000243A1 Pharmaceutical complex |
| 01/04/2001 | WO2001000241A2 Novel vector complexes and their use in gene therapy |
| 01/04/2001 | WO2001000233A1 Vaccine compositions using antigens encapsulated within alginate microspheres for oral administration and preparation process thereof |
| 01/04/2001 | WO2001000230A1 Drug composition containing lecithin-modified superoxide dismutase |
| 01/04/2001 | WO2001000226A1 Ophthalmic ointments for treating infective eye diseases |
| 01/04/2001 | WO2001000223A2 Multiple agent diabetes therapy |
| 01/04/2001 | WO2001000221A2 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 01/04/2001 | WO2001000200A1 Injection-administered antiviral preparation |
| 01/04/2001 | WO2001000182A1 Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| 01/04/2001 | WO2001000181A2 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 01/04/2001 | WO2001000180A1 Self-emulsifying systems containing anticancer medicament |
| 01/04/2001 | WO2001000179A1 Dry coated tablet and method for producing the same and production system |
| 01/04/2001 | WO2001000178A1 Tablets quickly disintegrating in mouth |
| 01/04/2001 | WO2001000177A1 Retard formulation of amoxicillin for oral administration |
| 01/04/2001 | WO2001000176A1 Divisible tablets |
| 01/04/2001 | WO2001000175A1 Mechanically stable pharmaceutical dosage forms, containing liquid or semi-solid surface-active substances |
| 01/04/2001 | WO2001000174A1 Liposomes |
| 01/04/2001 | WO2001000173A1 Method of regulating leakage of drug encapsulated in liposomes |
| 01/04/2001 | WO2001000157A1 Delivery of a sacrificial substrate to inhibit protease permeation into skin |
| 01/04/2001 | WO2001000154A1 Gel-based cosmetic composition |
| 01/04/2001 | WO2001000153A1 Process and composition for temporarily suppressing pain |
| 01/04/2001 | WO2001000139A1 Topical formulations comprising skin penetration agents and the use thereof |
| 01/04/2001 | WO2001000046A1 Use of nanoscale sterols and sterol esters |
| 01/04/2001 | WO2001000044A1 Novel chitosan-containing liquid compositions and methods for their preparation and use |
| 01/04/2001 | WO2001000038A1 An effervescent green tea extract formulation |
| 01/04/2001 | WO2000062769A3 Use of ap-1 activators to treat glaucoma and ocular hypertension |
| 01/04/2001 | WO2000062763A3 Carrier patch for the delivery of agents to the skin |
| 01/04/2001 | WO2000061611A3 Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences |
| 01/04/2001 | WO2000057917A3 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| 01/04/2001 | WO2000054797A3 Pharmaceutical compositions comprising tgf-beta |
| 01/04/2001 | WO2000054753A3 Novel tablets incorporating isoflavone plant extracts and methods of manufacturing them |
| 01/04/2001 | WO2000047235A3 Methods of stimulating angiogenesis |
| 01/04/2001 | DE19930794A1 Encapsulation of active agents, especially drugs, by diffusion into previously prepared particles, e.g. based on alginate, to give injectable slow release formulations |
| 01/04/2001 | DE19930454A1 Feste Paroxetin enthaltende Zubereitungen Solid preparations containing paroxetine |
| 01/04/2001 | DE19929361A1 Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen Mechanically stable pharmaceutical dosage forms containing liquid or semisolid surface-active substances |
| 01/04/2001 | CA2377585A1 Methods for making apo-2 ligand using divalent metal ions |
| 01/04/2001 | CA2377437A1 Antisense modulation of ship-2 expression |
| 01/04/2001 | CA2377204A1 Purification and stabilization of peptide and protein pharmaceutical agents |
| 01/04/2001 | CA2377132A1 Amorphous nitric esters and their pharmaceutical compositions |
| 01/04/2001 | CA2377086A1 Self-emulsifying systems containing anticancer medicament |
| 01/04/2001 | CA2376935A1 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 01/04/2001 | CA2376859A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 01/04/2001 | CA2376818A1 Use of nanoscale sterols and sterol esters |
| 01/04/2001 | CA2376714A1 Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers |
| 01/04/2001 | CA2375979A1 An effervescent green tea extract formulation |
| 01/04/2001 | CA2369839A1 Compositions of insulin and insulin-related peptide for treating diabetes |
| 01/03/2001 | EP1064989A1 Emulsion comprising a volatile fluorinated oil and a silicone surfactant, cosmetic composition comprising the said emulsion and use of said surfactant to prepare a stable emulsion |
| 01/03/2001 | EP1064953A2 Contrast media for diagnostic imaging comprising gas-filled microspheres |
| 01/03/2001 | EP1064950A1 Remedies for hepatitis |
| 01/03/2001 | EP1064946A2 Topical zinc compositions |
| 01/03/2001 | EP1064945A1 Therapeutic use of a helium/oxygen mixture, especially for treating asthma |
| 01/03/2001 | EP1064942A1 Sustained release preparations |
| 01/03/2001 | EP1064939A2 Transdermal systems for release of 5-HT3 receptor antagonists and use thereof for antiemetic treatment |
| 01/03/2001 | EP1064938A1 Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| 01/03/2001 | EP1064937A1 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 01/03/2001 | EP1064936A1 Novel composition of paroxetine methanesulfonate |
| 01/03/2001 | EP1064935A1 Solid thermoformable controlled-release pharmaceutical composition |
| 01/03/2001 | EP1064934A1 GRF-containing lyophilized pharmaceutical composition |
| 01/03/2001 | EP1064913A1 Microcaspules |
| 01/03/2001 | EP1064912A1 Microcapsules |
| 01/03/2001 | EP1064911A1 Microcapsules |
| 01/03/2001 | EP1064910A1 Microcapsules |
| 01/03/2001 | EP1064383A2 Interferon alpha plasmids and delivery systems, and methods of making and using the same |
| 01/03/2001 | EP1064293A1 Crystallization of lactitol, crystalline lactitol product and use thereof |
| 01/03/2001 | EP1064088A1 Fabrication of multilayer-coated particles and hollow shells via electrostatic self-assembly of nanocomposite multilayers on decomposable colloidal templates |
| 01/03/2001 | EP1064087A2 Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly |
| 01/03/2001 | EP1064010A1 Peptide compositions and formulations and use of same |
| 01/03/2001 | EP1063998A1 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor |
| 01/03/2001 | EP1063993A1 Paroxetine compositions |
| 01/03/2001 | EP1063985A1 Benzoates derivatives for inhibiting angiogenesis |
| 01/03/2001 | EP1063983A1 Transdermal therapeutic system (tts) containing oxybutynin |
| 01/03/2001 | EP1063977A1 Coated starch capsules and a process for producing them |
| 01/03/2001 | EP1063976A1 Tarch capsules containing microorganisms and/or polypeptides or proteins and a process for producing them |
| 01/03/2001 | EP1063975A1 Crosslinkable macromers bearing initiator groups |
| 01/03/2001 | EP1063973A1 Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
| 01/03/2001 | EP1063972A1 Polymer based rapidly dissolving tablets and production processes thereof |
| 01/03/2001 | EP1063971A1 Controlled release oral tablet having a unitary core |
| 01/03/2001 | EP1063970A1 Slow release microcapsules |
| 01/03/2001 | EP1063969A1 Topical formulation of oil-in-water type as a carrier for providing a reduced irritant effect |
| 01/03/2001 | EP1063968A1 Improved compositions for inhalation |
| 01/03/2001 | EP1063960A1 Composition for aroma delivery |
| 01/03/2001 | EP1063942A1 Liquid polymeric compositions for controlled release of bioactive substances |
| 01/03/2001 | EP1063885A1 Xylitol compositions for treating upper respiratory conditions |
| 01/03/2001 | EP0934060A4 Dietary supplements |